CALGB-80405

NCT00265850 📎

Regimen

Experimental
Cetuximab + FOLFOX or FOLFIRI
Control
Bevacizumab + FOLFOX or FOLFIRI

Population

KRAS exon 2 wild-type metastatic CRC, 1L, previously untreated.

Key finding

1L mCRC KRAS-wt (exon 2): mOS cetuximab 30.0 vs bevacizumab 29.0 mo (HR 0.88, 95% CI 0.77-1.01, p=0.08, NS); mPFS 10.4 vs 10.8 mo (HR 1.04, NS); ORR 59.6% vs 55.2% (p=0.13, NS); primary endpoint (mOS) not met — no superiority for either biologic

Source: PMID 28632865

Timeline

    Guideline citations

    • NCCN Colon (p.140)